What's in AIO-Studien-gGmbH's pipeline?

AIO-Studien-gGmbH has 8 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 7 in Phase 2, 1 in Phase 1.

Which companies overlap with AIO-Studien-gGmbH's portfolio?

Top competitors by shared drug class: Canadian Cancer Trials Group, Centre Georges Francois Leclerc, Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd., French Innovative Leukemia Organisation, GERCOR - Multidisciplinary Oncology Cooperative Group.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/aio-studien-ggmbh.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

AIO-Studien-gGmbH — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AIO-Studien-gGmbH pipeline: 0 marketed, 0 filed, 0 Phase 3, 7 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 7 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Canadian Cancer Trials Group · 1 shared drug class
Centre Georges Francois Leclerc · 1 shared drug class
Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. · 1 shared drug class
French Innovative Leukemia Organisation · 1 shared drug class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
National Research Center for Hematology, Russia · 1 shared drug class
Ospedale Santa Croce-Carle Cuneo · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for AIO-Studien-gGmbH:

Cite this brief

Drug Landscape (2026). AIO-Studien-gGmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aio-studien-ggmbh. Accessed 2026-05-17.